



Join the Instagram 30 Mile Dog Walk in September for the American Cancer Society!

The ACS is asking you to join in walking 30 miles in September, with your dog, to help them fight for a world without cancer. The ACS has a platinum rating on GuideStar – the highest possible! So you can join with confidence that your miles WILL make a difference in the lives of people with cancer and their families. Find more info here: [30 Mile Dog Walk in September](#)

DASHBOARD

Overall Improvement across all Screend clinics

24.25%

Number of additional patients screened since Screend began

6,616

Cologuard 90-Day Adherence Rate Screend-wide

57.4%

Cologuard 90-Day Adherence Rate for Rescreened Patients Screend-wide

82.7%

Cologuard Positive Rate Screend-wide

18.4%

P2P SHARING

“Cost and Quality are inseparable issues.” Bader & Bohr

SHOUT-OUTS

📣 Shout out to **First Care Health Center (Park River), Southwest Healthcare (Bowman), and McKenzie County Health Center (Watford City)** on achieving the highest Cologuard 90-Day Adherence Rates among Screend participating clinics, at **82.30%, 69.20% and 69.10%**, respectively! This correlates to 13 potential lives saved to date at First Care, 11 at Southwest and 9 at McKenzie County to date; and a total of **166 potential lives saved across the 20 Screend clinics!**

FEATURED RESOURCES

[Increasing Colorectal Cancer Screening Among LGBTQ+ Communities](#)

People who identify as lesbian, gay, bisexual, transgender, queer, questioning, or other diverse sexual orientations or gender identities (LGBTQ+) face barriers that make them less likely to get screened for colorectal cancer than the general population. This newly updated brief describes this community's unique barriers to CRC Screening and outlines action steps to support screening among the LGBTQ+ community.

[Flu-FIT/Flu-FOBT or how about Flu-mtsDNA \(Cologuard\)?](#)

Offering home based stool tests to patients at the time of their annual flu shots has helped clinical teams increase CRC Screening rates. Guidance for FluFIT programs was created before mtsDNA became as commonly used as it is today, but would be an excellent addition to the program. Find more information at <https://nccrt.org/resource/flufit-program/>

UPCOMING EVENTS

[Enhancing Colorectal Cancer Screening Through Effective Patient Navigation: Integrating CPSTF Recommendations for Economic Impact](#)

Host: American Cancer Society | National Navigation Roundtable
Date: September 11, 2024 from 1:00 pm – 2:30pm ET
Free Virtual Event

[Susan G. Komen Annual Navigation Nation Summit](#)

Date: Sept 12, 2024 | 10 am – 3 pm CST

[LeadU Live Sessions | \[Agenda\]\(#\) | \[Register\]\(#\)](#)

- September 11 – Chamberlain, SD | Americinn – 1981 E King St, Chamberlain, SD 57325
- September 18 – Fargo, ND | Armory Annex, 820 Center Ave, Moorhead, MN 56560
- September 19 – Bismarck, ND | Bismarck State College – NECE Building Rooms 431-433 – 1500 Edwards Ave, Bismarck, ND 58506

[The 3rd annual Summit on the Future of Rural Health Care,](#)

"Pioneering innovation in a shifting landscape."
Date: October 29, 2024 | [Register for Livestream](#)

[2024 ACS NCCRT Annual Meeting](#)

Must be a member to receive an invitation.
Date: November 20-22, 2024
Location: Omni Fort Worth - Forth Worth, Texas

NEWS

[Guardant Shield: Guardant Health, Inc. - \[Guardant Health's FDA-approved Shield™ Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer\]\(#\)](#)

Key Points:

- Commercially available as of 8/1/24
- Meetings requirements for Medicare coverage - covered once every three years
- Not yet available for commercial Insurance. Because it has not yet been included on the recommendation list by the USPSTF, Affordable Care Act plans (including Medicaid Expansion) are not yet required to cover it.
- Guardant's Shield sensitivity is generally around 83% and the specificity is about 90%, depending on age and other factors. This means about 17% of those with cancer would have a false negative on this test, and 10% of those without cancer or precancerous lesions would have a false positive.
- Cologuard sensitivity is around 94% and specificity is 91% to 95%, which means it has far fewer false negatives and false positives.
- The test would still be considered only a partial screening and would require a follow-on colonoscopy if the result is positive. A follow-on colonoscopy following any non-invasive test should be covered by all ACA plans and Medicaid Expansion plans, even if the initial non-invasive test is not covered.
- Self-pay cost is \$895 (subject to change)
- The sample would be processed in Guardant's lab - not in the local lab.

This publication is supported by the Centers for Disease Control and Prevention (CDC) under cooperative agreement NU58DP006762 awarded to Quality Health Associates of North Dakota. It contents are those of the author(s) and do not necessarily represent the official views of CDC.

CONTACTS

Nikki Medalen, MS, BSN

Quality Improvement Specialist
nmedalen@qualityhealthnd.org
701.989.6236

Carolyn Tuft

Quality Improvement Specialist
ctuft@qualityhealthnd.org
701.989.6238

Jon Gardner

Network Administrator
jgardner@qualityhealthnd.org
701.989.6237



Quality Health Associates
of North Dakota

41 36th Avenue NW
Minot, ND 58703
www.screend.org